PRMT5 Inhibitor Scaffolds Balancing Cancer Efficacy and Selectivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need to identify new compounds for the treatment of diseases associated with increased expression or activity of protein arginine methyltransferase 5 (PRMT5), which is implicated in various conditions including cancers, neurodegenerative disorders, inflammatory diseases, metabolic disorders, cardiovascular diseases, autoimmune disorders, and blood disorders.
Innovation Solution
Development of compounds of formulas (I), (II), (III), and (IV) that inhibit PRMT5 activity, providing methods for their use in treating such diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If PRMT5 inhibitors are developed to treat diseases, then disease treatment efficacy is improved, but compound specificity and selectivity become more difficult to achieve
Solution Approach 1:
The patent applies local quality by designing inhibitors with specific structural features that target particular regions or characteristics of PRMT5. The compounds contain specific functional groups and molecular arrangements (local properties) that enable selective binding to PRMT5 while distinguishing it from other methyltransferases, thereby achieving both efficacy and specificity
Solution Approach 2:
The patent employs parameter changes by systematically varying molecular parameters of the inhibitor compounds (such as substituent groups, molecular weight, hydrophobicity, and binding affinity) to optimize the balance between treatment efficacy and compound specificity. Different embodiments explore various chemical parameters to fine-tune the inhibitor's selectivity for PRMT5
2Adaptability or versatility
If new PRMT5 inhibitor compounds are developed, then treatment options for PRMT5-associated diseases are expanded, but development time and resource investment increase
Solution Approach 1:
The patent applies segmentation by dividing the inhibitor development into multiple series and embodiments (formulas I-IV with various substituents), allowing parallel exploration of different chemical structures and biological activities. This segmented approach enables efficient screening and optimization of multiple candidate compounds simultaneously, expanding treatment options while managing development resources
Solution Approach 2:
The patent employs universality by designing a core chemical scaffold (pyrazolo[3,4-d]pyrimidine) that serves as a universal platform for developing multiple PRMT5 inhibitors with different substituents. This multi-functional approach allows a single core structure to generate numerous derivative compounds with potentially different pharmacological profiles, accelerating the expansion of treatment options
Data Source
AI summary
Provided are compounds of formulas (I), (II), (III), and (IV), which effectively inhibit protein arginine methyltransferase 5 (PRMT5). Also provided are methods of using the compounds, including a method of treating cancer, a method of inhibiting the activity of PRMT5 in a cell, and a method of treating a disease associated with increased activity of PRMT5.